Multiple Sklerose – Neue Therapieoptionen

Die Multiple Sklerose (MS) ist eine chronisch entzündlich demyelinisierende Erkrankung des zentralen Nervensystems (ZNS). Mit einer jährlichen Inzidenz von 3,5–5/100 000 Einwohner stellt die MS die häufigste Ursache für dauerhafte Behinderung junger Erwachsener dar. Gemeinsames Charakteristikum aller Verlaufsvarianten ist eine vermutlich autoimmunologisch vermittelte Destruktion von Markscheiden (Myelin) und Axonen des ZNS mit resultierenden Funktionsstörungen. Neben der bekannten Standardtherapie haben sich in letzter Zeit weitere Therapieformen etabliert. In klinischen Studien werden weitere neue Therapien untersucht.

• Literatur

• 1 Lucchinetti C, Bruck W, Parisi J et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717
• 2 Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302
• 3 Bates D. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology 2011; 76: 14-25
• 4 Kieseier BC, Wiendl H, Leussink VI, Stuve O. Immunomodulatory treatment strategies in multiple sclerosis. J Neurol 2008; 255 (Suppl. 06) 15-21
• 5 Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910
• 6 Warnke C, Adams O, Gold R et al. Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?. Nervenarzt 2011; 82: 475-480
• 7 Rudick RA, O'Connor PW, Polman CH et al. 2010. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 2010; 68: 304-310
• 8 Kappos L, Radue EW, O'Connor P et al. 2010. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401
• 9 Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415
• 10 Giovannoni G, Comi G, Cook S et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362: 416-426
• 11 Kappos L, Gold R, Miller DH et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372: 1463-1472
• 12 O'Connor PW, Li D, Freedman MS et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66: 894-900
• 13 Comi G, Pulizzi A, Rovaris M et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371: 2085-2092
• 14 Goodman AD, Brown TR, Edwards KR et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010; 68: 494-502
• 15 Goodman AD, Brown TR, Krupp LB et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009; 373: 732-738
• 16 Wade DT, Collin C, Stott C, Duncombe P. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2010; 16: 707-714